School of Pharmacy

Publications in the Biomolecular Science and Medicinal Chemistry Division

Publications

Content
FISCHER, P.M. and GIANELLA-BORRADORI, A., 2005. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opinion on Investigational Drugs. 14(4), 457-477

Content
FISCHER, P.M., 2005. Protein-protein interactions in drug discovery Drug Design Reviews Online. 2(3), 179-207

Content
KRYSTOF, V., MCNAE, I.W., WALKINSHAW, M.D., FISCHER, P.M., MÜLLER, P., VOJTESEK, B., ORSÁG, M., HAVLÍCEK, L. and STRNAD, M., 2005. Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cellular and Molecular Life Sciences. 62(15), 1763-1771

Content
MCINNES, C., MEZNA, M. and FISCHER, P.M., 2005. Progress in the discovery of polo-like kinase inhibitors. Current Topics in Medicinal Chemistry. 5(2), 181-197

Content
RAYNAUD, F.I., WHITTAKER, S.R., FISCHER, P.M., MCCLUE, S., WALTON, M.I., BARRIE, S.E., GARRETT, M.D., ROGERS, P., CLARKE, S.J., KELLAND, L.R., VALENTI, M., BRUNTON, L., ECCLES, S., LANE, D.P. and WORKMAN, P., 2005. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202 Clinical Cancer Research. 11(13), 4875-4887

Content
MCINNES, C. and FISCHER, P.M., 2005. Strategies for the design of potent and selective kinase inhibitors. Current Pharmaceutical Design. 11(14), 1845-1863

Content
NUTLEY, B.P., RAYNAUD, F.I., WILSON, S.C., FISCHER, P.M., HAYES, A., GODDARD, P.M., MCCLUE, S.J., JARMAN, M., LANE, D.P. and WORKMAN, P., 2005. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Molecular Cancer Therapeutics. 4(1), 125-139

Content
UHRINOVA, S., UHRIN, D., POWERS, H., WATT, K., ZHELEVA, D., FISCHER, P.M., MCINNES, C. and BARLOW, P.N., 2005. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. Journal of Molecular Biology. 350(3), 587-598

Content
DEKKER, LODEWIJK V, DANIELS, ZOE, HICK, CAROLINE, ELSEGOOD, KATHRYN, BOWDEN, SARAH, SZESTAK, TADGE, BURLEY, J RUSSELL, SOUTHAN, ANDY, CRONK, DAVID and JAMES, IAIN F, 2005. Analysis of human Nav1.8 expressed in SH-SY5Y neuroblastoma cells. European Journal of Pharmacology. 528(1-3), 52-8

Content
BROWN, SEAN G, THOMAS, ALISON, DEKKER, LODEWIJK V, TINKER, ANDREW and LEANEY, JOANNE L, 2005. PKC-delta sensitizes Kir3.1/3.2 channels to changes in membrane phospholipid levels after M3 receptor activation in HEK-293 cells. American Journal of Physiology: Cell Physiology. 289(3), C543-56

Content
RENAULT, MARIE-ANGE, JALVY, SANDRA, POTIER, MYLèNE, BELLOC, ISABELLE, GENOT, ELISABETH, DEKKER, LODEWIJK V, DESGRANGES, CLAUDE and GADEAU, ALAIN-PIERRE, 2005. UTP induces osteopontin expression through a coordinate action of NFkappaB, activator protein-1, and upstream stimulatory factor in arterial smooth muscle cells. Journal of Biological Chemistry. 280(4), 2708-13

Content
DEKKER,L.V. and CRONK,D., 2005. Nav1.8 as a drug target for pain. In: COWARD,K. and BAKER,M.D., eds., Sodium channels, pain and analgesia Birkhäuser Publishing Ltd, Basel, CHE. 123-144

Content
NEBBIOSO, A., CLARKE, N., VOLTZ, E., GERMAIN, E., AMBROSINO, C., BONTEMPO, P., ALVAREZ, R., SCHIAVONE, E.M., FERRARA, F., BRESCIANI, F., WEISZ, A., DE LERA, A.R., GRONEMEYER, H. and ALTUCCI, L., 2005. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nature Medicine. 11(1), 77-84

Content
CLARKE, N., NEBBIOSO, A., ALTUCCI, L. and GRONEMEYER, H., 2005. TRAIL: at the center of drugable anti-tumor pathways Cell Cycle. 4(7), 914-918
Displaying 631 to 645 of 914
Previous … 41 42 43 44 45 … Next

School of Pharmacy

University of Nottingham
University Park
Nottingham, NG7 2RD

For all enquiries please visit:
www.nottingham.ac.uk/enquiry